Sacubitril/Valsartan and Elevated Prothrombin Time/International Normalized Ratio in the Absence of Anticoagulant Therapy: A Newly Recognized Potential Adverse Drug Reaction
{{output}}
Introduction: Sacubitril/valsartan is the first approved angiotensin receptor-neprilysin inhibitor (ARNI) and a cornerstone therapy for heart failure with reduced ejection fraction (HFrEF). While its clinical benefits are well es... ...
